• Journal of Pharmaceutical Investigation
• /
• v.12 no.1
• /
• pp.12-22
• /
• 1982

The experimental study have showed that the Polygonatum officinale All. contains diosgenin and ${\beta}-sitosterol$ as active components. Even though many experimental studies were reported, still there are many unknown actions of components from the plant. The purpose of this study was to elucidate the mechanism of hypoglycemic action of ether extract of Polygonatum officinale. The hypoglycemic effect of the ether extract was tested in hyperglycemic rats induced experimentally, The effect on plasma free fatty acid and the acute toxicity were also examined by using mouse. The hypoglycemic effect of the ether extract was compared with other oral hypoglycemic agents such as chlorpropamide and buformin. The ether extract of Polyonatum officinale showed a marked hypoglycemic effect by 1 hour after oral administration in hyperglycemic rats and rabbits but the ethanol extract did not exhibit the hypoglycemic effect. The hypoglycemic effect of the ether extract was potentiated by chlorpropamide while buformin was weak.

• Journal of The Korean Society of Clinical Toxicology
• /
• v.6 no.1
• /
• pp.42-44
• /
• 2008

Metformin which is an oral hypoglycemic agents, acts by enhancing insulin sensitivity, decreasing hepatic glucose production and increasing peripheral utilization of glucose. Deliberate self poisoning with oral hypoglycemic agents is rare. The lactic acidosis associated with metformin toxicity is well described in the medical literature. Metformin overdose even in otherwise healthy patients may produce a profound and life threatening lactic acidosis. We report a case of massive metformin ingestion(75g) in a patient presenting with lactic acidosis and hypotension. She died 24h after presenting to our emergency department despite bicarbonate treatment and hemofiltration therapy.

• Archives of Pharmacal Research
• /
• v.13 no.1
• /
• pp.108-112
• /
• 1990

It was confirmed that extracts of some plants were used in folklore medicine as hypoglycemic agents. Of these plants is Azadirachta indica ("neem") which grows in tropical regions. The present study deals with biochemical effects of the "neem" leaf water extract given orally to experimental aminals, especially the hypoglycemic characteristics. Normals as well as alloxan diabetic rats have been used in this work. The results showed that the "neem" leaf extract produced some hypoglycemia in normal rats when given in two doses, while in diabetic rats there was a decrease in blood sugar, but it could not alleviate the diabetic in body weight loss and high percentage mortality, especially with a high dose. It was observed increased with concomitant decrease in the liver fat as compared to normal levels. There was also a drop in liver proteins which was dose-related. The results were compared wiht those obtained with an oral hypoglycemic drug (Glibenclamide).glycemic drug (Glibenclamide).

• The Journal of Internal Korean Medicine
• /
• v.42 no.4
• /
• pp.718-726
• /
• 2021

This study presents a case of add-on traditional Korean medical treatments in a 77-year-old male patient with uncontrolled type 2 diabetes mellitus with conventional oral hypoglycemic agents. Chief complaints were uncontrolled glucose level and weight loss. The patient was treated with electroacupuncture (on ST36, CV4, and CV12), herbal medication, and lifestyle advice. The conventional oral hypoglycemic medications were maintained. After 12 weeks, the glycated hemoglobin A1c (HbA1c) decreased from 11.0% to 8.4%. There were significant abnormalities in the liver function and renal function tests, but no adverse event was reported. Further studies are needed to confirm the findings of this case.

• The Journal of the Korean life insurance medical association
• /
• v.17
• /
• pp.21-30
• /
• 1998

인슐린의존형당뇨병 환자의 혈당조절의 방법으로 먼저 식이요법과 운동이 권장되며, 이러한 방법으로 혈당조절이 만족스럽지 않을 때 경구혈당강하제를 사용하는 것은 혈당조절과 합병증 예방에 중요한 역할을 할 수 있다. 국내에서는 경구혈당강하제로 설폰요소제, 비구아나이드제인 메트포르민(metformin) 및 알파글루코시다제(${\alpha}$-glucosidase) 억제제인 아카보스(acarbose) 등이 사용되고 있다. 새로 개발중인 트로글리타존, 지방산 산화 억제제 등의 약제는 아직 임상에서 널리 사용되고 있지는 않다.

• Korean Journal of Clinical Pharmacy
• /
• v.34 no.2
• /
• pp.100-107
• /
• 2024

Background: The purpose of this study was to detect signals of adverse events (AEs) of DPP-IV inhibitors using the KIDs-Korea Adverse Event Reporting System (KAERS) database. Methods: This study was conducted using AEs reported from January 2009 to December 2018 in the KIDs-KAERS database. For signal detection, disproportionality analysis was performed. Signals of DPP-IV inhibitor that satisfied the data-mining indices of reporting odds ratio (ROR) were detected. Results: Among the total number of 10,364 AEs to all oral hypoglycemic agents, the number of reported AEs related to DPP-IV inhibitors was 1,674. Analysis of reported AEs of DPP-IV inhibitors at the SOC levels showed that Respiratory system disorders were the highest at 4.31 (95% CI 3.01-6.17), followed by Skin and appendages disorders at 2.04 (95% CI 1.74-2.38). When analyzing AEs reported at the PT level, pharyngitis was the highest at 73.90 (95% CI 17.59-310.49), followed by arthralgia at 6.08 (95% CI 2.04-18.11), and coughing at 5.21 (95% CI 2.07-13.15). Conclusions: Based on the result of the study, deeper consideration is required according to the characteristics of the patients in prescribing DPP-IV inhibitors among oral hypoglycemic agents, and continuous monitoring of the occurrence of related Adverse Drug Reactions during administration is also required.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1998.11a
• /
• pp.190-190
• /
• 1998

$_2$(5,7-dipropoxychrysin), $B_1$(chrysin7-O-toluate), $T_{0}$(5-hydroxy-7-butoxy-chrysin), and $O_1$(5- hydroxy-7 -octoxychrysin) are chrysin derivatives which have isolated from Mori Cortex Radicis. They exhibited strong hypoglycemic effect, so they can be developed for hypoglycemic agents. In this study, we evaluated the acute toxicity of $P_2$, $B_1$, $T_{0}$, and $O_1$ by a single oral administration in rats and mice. The male SD rats and the male ICR mice were divided into 5 groups, and each group was treated orally with 500mg/kg $P_2$, $B_1$, $T_{0}$, and $O_1$, and control respectively. 500mg/kg is the highest dosage which can be administered to mouse. Each group of mice were subdivided as the dosage, 5mg/kg, 20mg/kg, l00mg/kg, and 500mg/kg. After oral administration, we examined food consumption, clinical signs and mortality of each group for 12 days. We also examined body weight increment of animals before and after treatment. Then organ weights were examined on 13th day. There was no toxic effect in mortality, body weight changes, food consumption, clinical signs and organ weights. We found out that the $LD_{50}$ of $P_2$, $B_1$, $T_{0}$, and $O_1$ is more than 500mg/kg in rats.

• YAKHAK HOEJI
• /
• v.58 no.1
• /
• pp.71-79
• /
• 2014

Although Korean patients with type 2 diabetes mellitus (T2DM) are generally treated by western medicine, many of them strongly believe in the traditional oriental Sasang constitutional classification and depend on it for food, health supplements, and oriental medicines decision making. Sasang constitutional classification is a part of traditional Korean medicine that divides people into four constitutional types (Tae-Yang: TY, Tae-Eum: TE, So-Yang: SY, and So-Eum: SE), which differ in inherited characteristics such as appearance, personality traits, susceptibility to diseases, and drug responses. It is recommended for T2DM patients to control their blood glucose very well from early stages with drugs and diet. However, many T2DM patients respond differently to their drugs, even though they receive the same medicine. Therefore, the present study investigated whether Sasang constitutional type can explain the therapeutic differences between oral hypoglycemic agents (OHAs) therapy (mono, dual and triple drug therapy). Patients of 618 with T2DM diagnosis and Sasang constitutional type known who received both western and oriental medicine treatment in a hospital between April 2006 and April 2013 retrospectively studied. HbA1c (%) and blood glucose (mg/dl) levels before OHAs therapy and 3 month after were collected for metformin (MET) or sulfonylurea (SU) monotherapy, MET+SU dual therapy, MET+except SU (where was either alpha-glucosidase inhibitor, dipeptidyl peptidase-4 inhibitor, meglitinide or thiazolidinedione) dual therapy, and triple therapy, according to Sasang constitutional type. For statistical analysis, ANOVA was used and paired t-test by SPSS 19.0 where P values less than 0.05 were considered statistically significant. Pattern was similar levels of HbA1c and blood glucose and which was decreased in order of mono, MET+SU dual, MET+except SU dual and triple therapy. In all patients comparison, for the So-yang (SY) constitutional type, either monotherapy was less effective; for Te-eum (TE) type, MET+SU dual therapy was less effective while MET+except SU dual therapy was more effective and the triple therapy was less effective; and for So-eum (SE) type, the triple therapy was more effective. For the management of TE type it is recommended to use drugs except SU when dual therapy is needed, restrict triple therapy and consider dual and insulin therapy; for SY type it is recommended to follow current guidelines; and for SE type it is advisable to skip dual therapy and start the triple therapy early. Finally, the therapeutic response to OHAs is different among Korean T2DM patients with different Sasang constitutional types. Taken together, the choice of effective OHAs therapy for each type is necessary in order to minimize the poor control of blood glucose level, the risk of complications, and the costs from a failure of therapy.

• Proceedings of the PSK Conference
• /
• 2002.10a
• /
• pp.342.3-343
• /
• 2002

Non-insulin dependent diabetes mellitus (NIDDM) is characterized by hyperglycemia, hyperinsulinemia. and impaired insulin action. Insulin resistance is considered to be the underlying mechanism in the pathogenesis of type 2 diabetes. which also leads to dyslipidemia, hypertension. and obesity. Thazolidinediones are a class of oral insulin-sensitizing agents that improve glucose utilization without increasing insulin release. They significantly reduce glucose, lipid and insulin levels in rodent models of NIDDM and obesity, and recent clinical data support theri efficacy in obese diabetic patients. (omitted)

• Journal of Pharmacopuncture
• /
• v.16 no.4
• /
• pp.14-21
• /
• 2013

Objectives: The objective of this study was to examine how an integrated approach to type 2 diabetes mellitus treatment could improve glycemic control and immune-potentiating activities adherent to oral hypoglycemic agents along with a botanical compound, among primary care patients. Methods: In this study, we used the self-control and the group-control methods. Candidates meeting the trial conditions were selected from among volunteers who had taken the test substance for 45 days. During the trial, all groups were on a controlled diet; neither were the original medications nor their dosages changed. Results: The results showed that the botanical compound (Glyco-Persica$^{(R)}$) significantly reduced the main clinical symptoms in diabetes type 2. In the treatment group, 36 of 52 patients (69.23%) and in the control group 10 of 52 patients (19.23%) showed reduced symptoms, and this difference was statistically significant (P < 0.05). The fasting blood sugar in the treatment group after treatment compared with that before treatment and with that in the control group after treatment was statistically different (P < 0.05). The post-prandial glucose in the treatment group after treatment was significantly different from that before treatment and from that in the control group after treatment (P < 0.05); the post-prandial blood sugar in the treatment group was reduced by 8.98%. Conclusions: The results revealed that the botanical compound (Glyco-Persica$^{(R)}$) has significant hypoglycemic properties which affect main clinical symptoms in diabetes type 2. Body weight, blood pressure, heart rate, routine blood, stool and urine tests showed no meaningful negative changes after the course of treatment. There was no significant adverse reaction during the trial.